Other Cancer Types
Additional mebendazole oncology evidence across melanoma, pancreatic, colorectal, breast, and other cancer models
Mebendazole's pathway relevance extends across multiple cancers beyond the strongest ovarian, colorectal, breast, brain, and lung examples.
Additional evidence areas
Melanoma — ERK / MAPK-heavy biology makes this an especially interesting future direction
Pancreatic cancer — pathway logic suggests relevance, though the current note set is still broad rather than cancer-page-specific
Other ERK-driven tumours — including hepatic, oral, and some leukemic settings
Practical interpretation
This page acts as a holding space for additional cancers where the biological rationale is strong, but the current topic notes are not yet deep enough to justify full standalone pages.
References
Emerging Perspectives on the Antiparasitic Mebendazole as a Cancer Therapy
https://pmc.ncbi.nlm.nih.gov/articles/PMC9862092/
Mebendazole as a Candidate for Drug Repurposing in Oncology
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.